Lastly, the contribution of TGF-β1 to lymphedema fibrosis can potentially be mitigated with small molecule inhibitors or neutralizing antibodies, which have been shown to reduce the severity of lymphedema and enhance collateral lymphatic formation (Sano et al., 2020; Yoon et al., 2020). Here, TGFB1 is linked to lymphedema.